Fluconazolannoksella

Fluconazolannoksella is a Finnish term that translates roughly to the dose or dosing regimen of fluconazole, a triazole antifungal used to treat a range of fungal infections. The concept focuses on how much drug is given, how often, and for how long.

Fluconazole has high oral bioavailability and penetrates most body tissues, including the central nervous system. It is predominantly eliminated by the kidneys, so dose adjustments are often needed in renal impairment. It is effective against most Candida species and Cryptococcus species, among others.

In adults, fluconazole dosing is regimen-dependent. Uncomplicated vulvovaginal candidiasis commonly uses a single 150 mg oral dose. For other mucosal or systemic infections, daily doses typically range from 200 to 400 mg, and higher doses up to 800 mg daily may be used under specialist supervision, such as for cryptococcal meningitis. Pediatric dosing is usually weight-based and adjusted for age and organ function.

Safety and interactions: common adverse effects include nausea and headache; liver test abnormalities can occur rarely. Serious hepatotoxicity and QT prolongation have been reported. Fluconazole can interact with several drugs (for example warfarin, phenytoin, cyclosporine) through cytochrome P450 inhibition, so monitoring and dose adjustments may be necessary.

Dosing by fluconazolannoksella is an essential aspect of antifungal therapy. Because regimens depend on infection type, patient factors, and local guidelines, dosing should be determined by a clinician based on current recommendations.